Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrivon TherapeuticsACRV +1.16%35 EV-to-EBIT is 0.17 as of Aug. 13, 2026. GuruFocus rates ACRV with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 367 Biotechnology companies, Acrivon Therapeutics ranks better than 89.37% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Acrivon Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $0.00 Mil.
Acrivon Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrivon Therapeutics EV-to-EBIT Related Terms
Acrivon Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Acrivon Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acrivon Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrivon Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Acrivon Therapeutics's EV-to-EBIT falls into.
Acrivon Therapeutics's current Enterprise Value is $-13.37 Mil.
Acrivon Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrivon Therapeutics (ACRV) has a EV-to-EBIT of 0.17 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Acrivon Therapeutics and its competitors. According to the industry distribution chart, Acrivon Therapeutics ranks #39 out of 367 companies in the Biotechnology industry, placing it in the top 10.6%.
Is Acrivon Therapeutics' EV-to-EBIT too high?
Acrivon Therapeutics' current EV-to-EBIT is 0.17. The Biotechnology industry median EV-to-EBIT is 15.42. Acrivon Therapeutics' value of 0.17 is 98.9% below this industry median. Based on the distribution chart, Acrivon Therapeutics ranks #39 out of 367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acrivon Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' EV-to-EBIT compare to SPRO and BSEM?
According to the Biotechnology industry distribution chart, Acrivon Therapeutics ranks #39 out of 367 companies for EV-to-EBIT. This places Acrivon Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.42. Acrivon Therapeutics' value of 0.17 is 98.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.42, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrivon Therapeutics's current EV-to-EBIT of 0.17 is 98.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Acrivon Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrivon Therapeutics's current EV-to-EBIT is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current EV-to-EBIT of 0.17. The current EV-to-EBIT is 0.17 and 98.9% below the Biotechnology industry median of 15.42. Acrivon Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current EV-to-EBIT is 0.17 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
35GF Score
Get the complete analysis for ACRV
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRV has been successfully added to your 
